Sort   by:  
 Page size 
UnknownMRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Not available
S-EPMC10618744 | biostudies-literature
UnknownThe KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Not available
S-EPMC6954325 | biostudies-literature
UnknownPhase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma.
Not available
S-EPMC9940695 | biostudies-literature
UnknownFirst-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Not available
S-EPMC9433959 | biostudies-literature
UnknownAntitumor activity in RAS-driven tumors by blocking AKT and MEK.
Not available
S-EPMC4335074 | biostudies-literature
UnknownEffects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
Not available
S-EPMC9647563 | biostudies-literature
UnknownReduced lung-cancer mortality with low-dose computed tomographic screening.
Not available
S-EPMC4356534 | biostudies-literature
UnknownEndovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
Not available
S-EPMC9975904 | biostudies-literature
UnknownPatient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.
Not available
S-EPMC9975919 | biostudies-literature
UnknownEffects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study.
Not available
S-EPMC9210173 | biostudies-literature
Sort   by:  
 Page size